News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,339 Results
Type
Article (15826)
Company Profile (114)
Press Release (76399)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (15288)
Career Advice (291)
Deals (4248)
Drug Delivery (14)
Drug Development (11697)
Employer Resources (15)
FDA (2036)
Job Trends (2086)
News (33774)
Policy (3372)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (2)
Academia (885)
Academic (1)
Accelerated approval (8)
Adcomms (2)
Allergies (33)
Alliances (3056)
ALS (18)
Alzheimer's disease (387)
Antibody-drug conjugate (ADC) (22)
Approvals (2121)
Artificial intelligence (59)
Autoimmune disease (12)
Automation (1)
Bankruptcy (42)
Best Places to Work (1535)
BIOSECURE Act (1)
Biosimilars (21)
Biotechnology (71)
Bladder cancer (34)
Brain cancer (10)
Breast cancer (112)
Cancer (792)
Cardiovascular disease (110)
Career advice (259)
Career pathing (3)
CAR-T (36)
CDC (17)
Cell therapy (77)
Cervical cancer (6)
Clinical research (9530)
Collaboration (107)
Company closure (2)
Compensation (2)
Complete response letters (4)
COVID-19 (661)
CRISPR (14)
C-suite (64)
Cystic fibrosis (20)
Data (1195)
Depression (21)
Diabetes (93)
Diagnostics (896)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (15)
Drug pricing (28)
Drug shortages (1)
Duchenne muscular dystrophy (15)
Earnings (5507)
Editorial (24)
Employer branding (4)
Employer resources (15)
Events (7409)
Executive appointments (61)
FDA (2471)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (129)
Gene editing (21)
Generative AI (7)
Gene therapy (69)
GLP-1 (177)
Government (644)
Grass and pollen (1)
Guidances (44)
Healthcare (2674)
HIV (12)
Huntington's disease (3)
IgA nephropathy (14)
Immunology and inflammation (21)
Immuno-oncology (7)
Indications (16)
Infectious disease (699)
Inflammatory bowel disease (39)
Inflation Reduction Act (2)
Influenza (10)
Intellectual property (14)
Interviews (45)
IPO (2842)
IRA (7)
Job creations (619)
Job search strategy (211)
JPM (15)
Kidney cancer (2)
Labor market (3)
Layoffs (62)
Leadership (8)
Legal (669)
Liver cancer (19)
Longevity (2)
Lung cancer (134)
Lymphoma (50)
Machine learning (7)
Management (3)
Manufacturing (40)
MASH (28)
Medical device (1751)
Medtech (1759)
Mergers & acquisitions (1551)
Metabolic disorders (211)
Multiple sclerosis (23)
NASH (8)
Neurodegenerative disease (40)
Neuropsychiatric disorders (10)
Neuroscience (551)
NextGen: Class of 2026 (879)
Non-profit (752)
Obesity (88)
Opinion (52)
Ovarian cancer (30)
Pain (28)
Pancreatic cancer (34)
Parkinson's disease (33)
Partnered (4)
Patents (24)
Patient recruitment (32)
Peanut (17)
People (5623)
Pharmaceutical (22)
Pharmacy benefit managers (7)
Phase 1 (2187)
Phase 2 (3640)
Phase 3 (4058)
Pipeline (620)
Policy (54)
Postmarket research (670)
Preclinical (1723)
Press Release (32)
Prostate cancer (35)
Psychedelics (10)
Radiopharmaceuticals (24)
Rare diseases (112)
Real estate (713)
Recruiting (6)
Regulatory (2734)
Reports (5)
Research institute (696)
Resumes & cover letters (43)
Rett syndrome (5)
RNA editing (3)
RSV (17)
Schizophrenia (21)
Series A (20)
Series B (18)
Service/supplier (2)
Sickle cell disease (10)
Special edition (4)
Spinal muscular atrophy (16)
Sponsored (4)
Startups (344)
Supply chain (7)
Tariffs (4)
The Weekly (9)
Vaccines (167)
Venture capital (8)
Weight loss (76)
Women's health (9)
Worklife (4)
Date
Last 7 days (72)
Last 30 days (237)
Last 365 days (3443)
2026 (319)
2025 (3474)
2024 (4077)
2023 (4334)
2022 (7060)
2021 (8715)
2020 (8207)
2019 (5910)
2018 (4696)
2017 (4127)
2016 (4406)
2015 (5387)
2014 (3911)
2013 (3345)
2012 (3451)
2011 (3561)
2010 (3101)
Location
Africa (124)
Alabama (5)
Alaska (2)
Arizona (34)
Arkansas (3)
Asia (4836)
Australia (1107)
California (1156)
Canada (406)
China (153)
Colorado (40)
Connecticut (58)
Delaware (53)
Europe (12374)
Florida (178)
Georgia (39)
Idaho (6)
Illinois (100)
India (4)
Indiana (83)
Iowa (2)
Japan (68)
Kansas (6)
Kentucky (7)
Louisiana (4)
Maine (2)
Maryland (92)
Massachusetts (787)
Michigan (16)
Minnesota (94)
Mississippi (3)
Missouri (38)
Montana (3)
Nebraska (1)
Nevada (13)
New Hampshire (10)
New Jersey (372)
New Mexico (3)
New York (450)
North Carolina (154)
North Dakota (2)
Northern California (586)
Ohio (32)
Oklahoma (4)
Oregon (4)
Pennsylvania (281)
Puerto Rico (1)
Rhode Island (10)
South America (137)
South Carolina (4)
Southern California (428)
Tennessee (26)
Texas (141)
United States (4375)
Utah (31)
Virginia (42)
Washington D.C. (7)
Washington State (104)
Wisconsin (12)
92,339 Results for "wall street journal".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
November 12, 2025
·
3 min read
·
Dan Samorodnitsky
FDA
Wall Street the Main Beneficiary of FDA’s Real-Time CRL Disclosures
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a way that, while positioned as a public health measure, also grants investors greater visibility into regulatory decisions. Experts question whether this is the agency’s proper remit.
September 29, 2025
·
6 min read
·
Ben Hargreaves
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
CDC
RFK Jr. Blames US COVID Deaths on Chronic Disease, Announcing CDC Reorganization
In an opinion piece in the
Wall Street Journal
, Health Secretary Robert F. Kennedy Jr. said he will roll chronic disease programs into a new Administration for a Healthy America.
September 3, 2025
·
2 min read
·
Dan Samorodnitsky
Government
Monarez Blasts Partisan Public Health Policy at CDC Under RFK Jr.
Ousted CDC Director Susan Monarez claimed in an op-ed published in
The
Wall Street Journal
Thursday that she was fired for refusing to rubber-stamp COVID-19 recommendations to be made by an advisory panel that has expressed “antivaccine rhetoric.”
September 5, 2025
·
2 min read
·
Tristan Manalac
Government
American Medical Association Urges RFK Jr. to Maintain Preventive Task Force
Health Secretary Robert F. Kennedy Jr. wants to remove all members of the USPSTF for being too “woke,” according to reporting by the
Wall Street Journal
. An HHS spokesperson, however, says no final decision has been made about the panel.
July 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET
June 26, 2025
·
2 min read
Press Releases
Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub-Lite-Wall™, Advancing the Future of Catheter Innovation
January 30, 2026
·
3 min read
Press Releases
Overcoming the Wall: How Far Has BBB-Crossing Antibody Technology Truly Advanced? - Commentary by Unexakorea
January 26, 2026
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida
May 21, 2025
·
4 min read
1 of 9,234
Next
